1. Adelaide Research & Scholarship

Search


Current filters:



Start a new search
Add filters:

Use filters to refine the search results.

 | 
Results 21-30 of 60 (Search time: 0.002 seconds).
Item hits:
PreviewIssue DateTitleAuthor(s)
2013Salvage second hematopoietic cell transplantation in myelomaMichaelis, L.; Saad, A.; Zhong, X.; Le-Rademacher, J.; Freytes, C.; Marks, D.; Lazarus, H.; Bird, J.; Holmberg, L.; Kamble, R.; Kumar, S.; Lill, M.; Meehan, K.; Saber, W.; Schriber, J.; Tay, J.; Vogl, D.; Wirk, B.; Savani, B.; Gale, R.; et al.
2013PIK3CA and PTEN gene and exon mutation-specific clinicopathologic and molecular associations in colorectal cancerDay, F.; Jorissen, R.; Lipton, L.; Mouradov, D.; Sakthianandeswaren, A.; Christie, M.; Li, S.; Tsui, C.; Tie, J.; Desai, J.; Xu, Z.; Molloy, P.; Whitehall, V.; Leggett, B.; Jones, I.; McLaughlin, S.; Ward, R.; Hawkins, N.; Ruszkiewicz, A.; Moore, J.; et al.
2015Crohn's disease management after intestinal resection: a randomised trialDe Cruz, P.; Kamm, M.; Hamilton, A.; Ritchie, K.; Krejany, E.; Gorelik, A.; Liew, D.; Prideaux, L.; Lawrance, I.; Andrews, J.; Bampton, P.; Gibson, P.; Sparrow, M.; Leong, R.; Florin, T.; Gearry, R.; Radford-Smith, G.; Macrae, F.; Debinski, H.; Selby, W.; et al.
2013Phase III randomized, placebo-controlled study of cetuximab plus brivanib alaninate versus cetuximab plus placebo in patients with metastatic, chemotherapy-refractory, wild-type K-RAS colorectal carcinoma: The NCIC clinical trials group and AGITG co.Siu, L.; Shapiro, J.; Jonker, D.; Karapetis, C.; Zalcberg, J.; Simes, J.; Couture, F.; Moore, M.; Price, T.; Siddiqui, J.; Nott, L.; Charpentier, D.; Liauw, W.; Sawyer, M.; Jefford, M.; Magoski, N.; Haydon, A.; Walters, I.; Ringash, J.; Tu, D.; et al.
2012Glucokinase links Kruppel-like factor 6 to the regulation of hepatic insulin sensitivity in nonalcoholic fatty liver diseaseBechmann, L.; Gastaldelli, A.; Vetter, D.; Patman, G.; Pascoe, L.; Hannivoort, R.; Lee, U.; Fiel, I.; Munoz, U.; Ciociaro, D.; Lee, Y.; Buzzigoli, E.; Miele, L.; Hui, K.; Bugianesi, E.; Burt, A.; Day, C.; Mari, A.; Agius, L.; Walker, M.; et al.
2013Loss-of-function mutations in SIM1 contribute to obesity and Prader-Willi-like featuresBonnefond, A.; Raimondo, A.; Stutzmann, F.; Ghoussaini, M.; Ramachandrappa, S.; Bersten, D.; Durand, E.; Vatin, V.; Balkau, B.; Lantieri, O.; Raverdy, V.; Pattou, F.; Van Hul, W.; Van Gaal, L.; Peet, D.; Weill, J.; Miller, J.; Horber, F.; Goldstone, A.; Driscoll, D.; et al.
2016Disruptive de novo mutations of DYRK1A lead to a syndromic form of autism and IDvan Bon, B.W.M.; Coe, B.P.; Bernier, R.; Green, C.; Gerdts, J.; Witherspoon, K.; Kleefstra, T.; Willemsen, M.H.; Kumar, R.; Bosco, P.; Fichera, M.; Li, D.; Amaral, D.; Cristofoli, F.; Peeters, H.; Haan, E.; Romano, C.; Mefford, H.C.; Scheffer, I.; Gecz, J.; et al.
2012Pemetrexed versus pemetrexed and carboplatin as second-line chemotherapy in advanced non-small-cell lung cancer: Results of the GOIRC 02-2006 randomized phase II study and pooled analysis with the NVALT7 trialArdizzoni, A.; Tiseo, M.; Boni, L.; Vincent, A.; Passalacqua, R.; Buti, S.; Amoroso, D.; Camerini, A.; Labianca, R.; Genestreti, G.; Boni, C.; Ciuffreda, L.; Di Costanzo, F.; De Marinis, F.; Crino, L.; Santo, A.; Pazzola, A.; Barbieri, F.; Zilembo, N.; Colantonio, I.; et al.
2011A novel recurrent mutation in MITF predisposes to familial and sporadic melanomaYokoyama, S.; Woods, S.; Boyle, G.; Aoude, L.; MacGregor, S.; Zismann, V.; Gartside, M.; Cust, A.; Haq, R.; Harland, M.; Taylor, J.; Duffy, D.; Holohan, K.; Dutton-Regester, K.; Palmer, J.; Bonazzi, V.; Stark, M.; Symmons, J.; Law, M.; Schmidt, C.; et al.
2014Nonsense mutations in the shelterin complex genes ACD and TERF2IP in familial melanomaAoude, L.; Pritchard, A.; Robles-Espinoza, C.; Wadt, K.; Harland, M.; Choi, J.; Gartside, M.; Quesada, V.; Johansson, P.; Palmer, J.; Ramsay, A.; Zhang, X.; Jones, K.; Symmons, J.; Holland, E.; Schmid, H.; Bonazzi, V.; Woods, S.; Dutton-Regester, K.; Stark, M.; et al.

Discover